First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers.

Abstract

The current pilot study provides evidence on the improvement of the clinical symptoms and the good tolerability of Artenimol-R in patients with advanced carcinoma of the cervix uteri. A survival trial with Artenimol-R in advanced patients is warranted.